Glucose responsive insulin microneedle patch based on photopolymerization and preparation method thereof
The glucose-responsive insulin microneedle patch prepared through photopolymerization technology uses benzeneboronic acid hydrogel to combine with glucose, which solves the pain and poor compliance problems of the existing insulin injection methods, realizes intelligent insulin release, and effectively controls blood sugar levels. Reduce the risk of hypoglycemia.
Patent Information
- Application Number
- CN202411056530.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-22
AI Technical Summary
The existing insulin injection methods have pain, poor compliance and low blood sugar risks, making it difficult to effectively control blood sugar levels within the normal range.
Using photopolymerization-based glucose-responsive insulin microneedle patches, a photopolymerization technology is used to prepare microneedle patches with glucose response capabilities to achieve intelligent release of insulin.
It realizes painless and intelligently responsive blood sugar regulation, which can quickly or slowly release insulin according to changes in glucose concentration, effectively prevent the risk of hypoglycemia, and improves insulin drug loading and biocompatibility.
Smart Images

Figure BDA0004976600520000021 
Figure BDA0004976600520000022 
Figure BDA0004976600520000031
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedical materials, and specifically relates to a glucose-responsive insulin microneedle patch based on photopolymerization and a preparation method thereof. Background Art
[0002] Diabetes is a syndrome characterized by high blood sugar levels, which causes a series of metabolic disorders such as protein, fat and electrolytes due to insufficient insulin secretion or reduced insulin sensitivity of target tissue cells. Diabetic patients need regular blood sugar monitoring and insulin management.
[0003] Injection of insulin is painful and patient compliance is poor. Excessive injection of insulin can lead to hypoglycemia. In severe cases, the patient may fall into a coma or even suffer brain damage.
[0004] Microneedles are micro needles with a length of 100-1000μm, which can effectively penetrate the stratum corneum of the skin and reach the superficial surface without damaging the blood vessels and nerves in the dermis. Therefore, they can painlessly deliver small molecules, peptides, nucleic acids and other drugs, and can well combine the advantages of injection and patch. As a non-invasive drug delivery method, microneedles improve the problem of poor compliance of injections.
[0005] In order to control blood sugar concentration within the normal range (3.9-10mmol / L), the concept of a "closed-loop" insulin delivery system was proposed. The "closed-loop" insulin delivery system can monitor human blood sugar in real time and release insulin on demand, accelerating the release of drugs when blood sugar is high and slowing the release of drugs when blood sugar is low, thereby avoiding hypoglycemia.
[0006] Phenylboronic acid and its derivatives can form a negatively charged tetrahedral structure at the pH of human body fluids, which can specifically bind to glucose, and are therefore selected as glucose molecule recognition response units. The release rate of the phenylboronic acid-containing gel can be controlled by the change in charge after phenylboronic acid binds to glucose and the swelling degree of the gel. Summary of the invention
[0007] The purpose of the present invention is to provide a glucose-responsive insulin microneedle patch based on photopolymerization and a preparation method thereof.
[0008] In order to solve the problems in the background technology, the present invention provides a glucose-responsive insulin microneedle patch based on photopolymerization. The glucose-responsive insulin microneedle patch is a phenylboronic acid hydrogel-based sugar-sensitive microneedle patch. The present invention aims to select phenylboronic acid-based monomers and vinyl-containing monomers to obtain a glucose-responsive insulin microneedle patch with glucose responsiveness through photopolymerization. The preparation process of the present invention is simple, and the prepared glucose-responsive insulin microneedle patch has excellent mechanical strength, can puncture the skin, has a regular structure, has good responsiveness to changes in glucose concentration, can control blood sugar within a normal range, and effectively prevent the risk of hypoglycemia.
[0009] In a first aspect of the present invention, a glucose-responsive insulin microneedle patch is provided, comprising a substrate and a microneedle array formed on the substrate, wherein the substrate and the microneedle array are respectively formed by photopolymerization and curing of a first functional material and a second functional material in the presence of a solvent monomer, a crosslinking agent and a photoinitiator, and the microneedle array contains drug molecules;
[0010] The first functional material is a compound represented by the following formula A, and its tautomers:
[0011]
[0012] In formula A, R is selected from C2-C6 alkenyl and -NH-CO-C2-C6 alkenyl;
[0013] The second functional material has a structure shown in Formula II:
[0014]
[0015] wherein n is selected from 1, 2, 3 or 4.
[0016] The second aspect of the present invention provides a method for preparing the glucose-responsive insulin microneedle patch according to the first aspect of the present invention, comprising the steps of:
[0017] (1) preparing a base solution and a needle solution, wherein the base solution comprises a solvent monomer, a functional material, a cross-linking agent and a photoinitiator; and the needle solution comprises a solvent monomer, a functional material, a cross-linking agent, a photoinitiator and a drug molecule;
[0018] (2) placing the needle body solution in a microneedle mold, wherein the needle body solution is completely distributed in the needle body portion of the microneedle mold, and then adding the base solution into the microneedle mold;
[0019] (3) placing the microneedle mold containing the needle body solution and the substrate solution obtained in step (2) under ultraviolet light to cause the needle body solution and the substrate solution to undergo a polymerization reaction to form a cured microneedle patch;
[0020] (4) Drying the solidified microneedle patch to obtain the glucose-responsive insulin microneedle patch.
[0021] The third aspect of the present invention provides the use of the second functional material represented by formula II in the preparation of a glucose-responsive insulin microneedle patch.
[0022] BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1This is the NMR spectrum of D-glucosamidoethyl methacrylate prepared in Preparation Example 1.
[0024] Figure 2 This is a scanning electron microscope image of the glucose-responsive insulin microneedle patch prepared in Example 1.
[0025] Figure 3 This is a fluorescence inverted microscope image of the glucose-responsive insulin microneedle patch prepared in Example 2.
[0026] Figure 4 This is the result of the in vitro insulin release experiment in Example 5.
[0027] Figure 5 These are the results of the insulin in vivo glucose-lowering experiment in Example 6. DETAILED DESCRIPTION
[0028] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.
[0029] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.
[0030] Herein, “comprising”, “including”, “containing” and similar terms encompass the meanings of “consisting essentially of” and “consisting of”. For example, when “A comprises B and C” is disclosed herein, “A consists essentially of B and C” and “A consists of B and C” should be deemed to be disclosed herein.
[0031] In this article, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are only for brevity and convenience. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values within the range (including integers and fractions).
[0032] In this document, unless otherwise specified, percentage refers to mass percentage and ratio refers to mass ratio.
[0033] Herein, when describing embodiments or examples, it should be understood that they are not used to limit the present invention to these embodiments or examples. On the contrary, all substitutes, improvements and equivalents of the methods and materials described in the present invention can be included in the scope limited by the claims.
[0034] Herein, as used herein, the term "alkenyl" refers to a straight or branched hydrocarbon chain group consisting only of carbon atoms and hydrogen atoms, containing at least one double bond, connected to the rest of the molecule by a single bond. In some embodiments, alkenyl contains 2 to 6 carbon atoms ("C2-C6 alkenyl"), preferably contains 2 to 5 carbon atoms ("C2-C5 alkenyl"), more preferably contains 2 to 4 carbon atoms ("C2-C4 alkenyl"). Non-limiting examples of alkenyl include but are not limited to vinyl, propenyl, allyl, butenyl, but-1-enyl, but-2-enyl, pentenyl, penta-1-enyl, pentadienyl, penta-1,4-dienyl, etc.
[0035] In this article, "tautomers" refers to a special type of isomerism. Its characteristics are that there are two isomers containing heteroatoms (such as nitrogen, oxygen or sulfur atoms), and their structural differences are only in the migration of protons and corresponding double bonds. These two isomers coexist in an equilibrium system and transform into each other at a relatively high rate. Keto-enol tautomerism is a common phenomenon, which can be catalyzed by acids or bases.
[0036] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.
[0037] Herein, the test method of the swelling rate is as follows. The initial mass of the glucose-responsive insulin microneedle patch prepared by the present invention is weighed. Then the glucose-responsive insulin microneedle patch is immersed in 5 mL of PBS solution (pH = 7.4), and the glucose-responsive insulin microneedle patch is taken out at regular intervals, and the mass is weighed after wiping off the excess liquid on the surface, and the swelling rate is calculated using the following formula:
[0038]
[0039] Where m1 is the initial mass of the glucose-responsive insulin microneedle patch, m t The mass of the glucose-responsive insulin microneedle patch after immersion for different times.
[0040] The present invention obtains a glucose-responsive insulin microneedle patch with glucose responsiveness through photopolymerization. The present invention provides a method for preparing a glucose-responsive insulin microneedle patch, comprising the steps of:
[0041] (1) preparing a base solution and a needle solution, wherein the base solution comprises a solvent monomer, a functional material, a cross-linking agent and a photoinitiator; and the needle solution comprises a solvent monomer, a functional material, a cross-linking agent, a photoinitiator and a drug molecule;
[0042] (2) placing the needle body solution in a microneedle mold, wherein the needle body solution is completely distributed in the needle body portion of the microneedle mold, and then adding the base solution into the microneedle mold;
[0043] (3) placing the microneedle mold containing the needle body solution and the substrate solution obtained in step (2) under ultraviolet light to cause the needle body solution and the substrate solution to undergo a polymerization reaction to form a cured microneedle patch;
[0044] (4) Drying the solidified microneedle patch to obtain the glucose-responsive insulin microneedle patch.
[0045] In some embodiments, the functional material includes a first functional material and a second functional material. The first functional material may be a compound represented by the following formula A, and its tautomers:
[0046]
[0047] In formula A, R is selected from C2-C6 alkenyl and -NH-CO-C2-C6 alkenyl.
[0048] In some embodiments, the C2-C6 alkenyl group is vinyl or propenyl. In some embodiments, the first functional material can be selected from one or more of acrylamidophenylboronic acid (such as 2-acrylamidophenylboronic acid, 3-acrylamidophenylboronic acid and 4-acrylamidophenylboronic acid) and vinylphenylboronic acid (such as 4-vinylphenylboronic acid), preferably 3-acrylamidophenylboronic acid.
[0049] The present invention provides a second functional material having a structure shown in Formula II:
[0050]
[0051] wherein n is selected from 1, 2, 3 or 4.
[0052] The second functional material of the present invention can be used to prepare the glucose-responsive insulin microneedle patch of the present invention.
[0053] In some embodiments, the second functional material of the present invention can be selected from one or more of D-glucosamidomethyl methacrylate, D-glucosamidoethyl methacrylate and D-glucosamidopropyl methacrylate, preferably D-glucosamidoethyl methacrylate.
[0054] In the photopolymerization curing reaction of preparing the glucose-responsive insulin microneedle patch of the present invention, the solvent monomer also participates in the polymerization. In some embodiments, the solvent monomer is selected from one or more of N-vinyl pyrrolidone, hydroxyethyl methacrylate, ethyl methacrylate and ethyl 3-(dimethylamino)acrylate; preferably, the solvent monomer is N-vinyl pyrrolidone.
[0055] In some embodiments, the crosslinking agent is selected from one or more of 1,4-butylene glycol diacrylate, itaconic acid, methacrylic acid, methylene bisacrylamide and ethylene glycol dimethacrylate; preferably ethylene glycol dimethacrylate.
[0056] In some embodiments, the photoinitiator is selected from one or more of lithium phenyl-2,4,6-trimethylbenzoyl phosphite, 2,4,6-trimethylbenzoyl diphenylphosphine, phenyl bis(2,4,6-trimethylbenzoyl), ethyl 2,4,6-trimethylbenzoyl phenylphosphonate and 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (photoinitiator 2959); preferably 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone.
[0057] In some embodiments, the drug molecule is selected from one or more of animal insulin, human insulin and human insulin analogs. Human insulin analogs can be selected from one or more of insulin lispro, insulin glargine, insulin aspart and insulin detemir. In some embodiments, the animal insulin is porcine insulin.
[0058] In some embodiments, in the needle solution, the mass percentage of each component is: the solvent monomer is 58%-90%, the first functional material is 2-30%, the second functional material is 1-10%, the cross-linking agent is 0.1%-5%, the photoinitiator is 0.1%-2%, and the drug molecule is 0.01%-30%. Preferably, in the needle solution, the mass fraction of the solvent monomer is 60%, 70%, 73%, 75%, 80%, 83%, 88%, 90%, or in the range between any two numerical values. Preferably, in the needle solution, the mass fraction of the first functional material is 5%, 6%, 8%, 10%, 15%, 18%, 20%, 25%, or in the range between any two numerical values. Preferably, in the needle solution, the mass fraction of the second functional material is 2%, 4%, 5%, 6%, 8%, or in the range between any two numerical values. Preferably, in the needle solution, the mass fraction of the crosslinker is 0.3%, 0.5%, 0.6%, 0.7%, 0.8%, 1%, 3%, or a range between any two values. Preferably, in the needle solution, the mass fraction of the photoinitiator is 0.5%, 1%, 1.3%, 1.5%, 1.6%, 1.7%, 1.9%, or a range between any two values. Preferably, in the needle solution, the mass fraction of the drug molecule is 0.05%, 0.1%, 0.3%, 0.5%, 0.8%, 1.3%, 1.5%, 2%, 5%, 10%, 20%, or a range between any two values.
[0059] In some embodiments, in the base solution, the mass percentage of each component is: the solvent monomer is 50%-95%, the first functional material is 2-30%, the second functional material is 1-10%, the cross-linking agent is 0.1%-5%, and the photoinitiator is 0.1%-2%. Preferably, in the base solution, the mass fraction of the solvent monomer is 60%, 70%, 73%, 75%, 80%, 83%, 88%, 90%, or in the range between any two numerical values. Preferably, in the base solution, the mass fraction of the first functional material is 5%, 6%, 8%, 10%, 15%, 18%, 20%, 25%, or in the range between any two numerical values. Preferably, in the base solution, the mass fraction of the second functional material is 2%, 4%, 5%, 6%, 8%, or in the range between any two numerical values. Preferably, in the base solution, the mass fraction of the crosslinker is 0.3%, 0.5%, 0.6%, 0.7%, 0.8%, 1%, 3%, or any range between two values. Preferably, in the base solution, the mass fraction of the photoinitiator is 0.5%, 1%, 1.3%, 1.5%, 1.6%, 1.7%, 1.9%, or any range between two values.
[0060] In some embodiments, in the needle solution and the substrate solution, the molar ratio of the first functional material to the second functional material is (20:1) to (1:10), for example, (15:1) to (1:1) or (10:1) to (1:10).
[0061] In step (1), the components of the base solution are weighed according to the mass fractions described in any embodiment of the present invention, and then ultrasonicated after mixing; and / or, the components of the needle body solution are weighed according to the mass fractions described in any embodiment of the present invention, and then ultrasonicated after mixing. Ultrasound can help dissolution and remove bubbles. The ultrasonic time can be 10-60 minutes, such as 20-40 minutes or 30 minutes.
[0062] In step (2), the needle body solution is placed in a microneedle mold and centrifuged once, and the needle body solution is completely distributed in the needle body part of the microneedle mold; then the substrate solution is added to the microneedle mold and centrifuged twice. The rotation speed of the first centrifugation can be 4000-6000rpm, such as 4500-5500rpm or 5000rpm. The time of the first centrifugation can be 2-30min, such as 5-20min or 10min. The rotation speed of the second centrifugation can be 4000-6000rpm, such as 4500-5500rpm or 5000rpm. The time of the second centrifugation can be 2-30min, such as 5-20min or 10min.
[0063] In step (3), the wavelength of the ultraviolet light may be 330-420 nm, such as 350-400 nm, 360-380 nm or 365 nm. The power of the ultraviolet light may be 100-300 W, such as 150-250 W, 180-220 W or 190-200 W. The illumination time of the ultraviolet light may be 5-20 min, such as 8-18 min or 10-15 min.
[0064] In step (4), the drying time may be 24-72 hours, such as 30-60 hours or 36-48 hours.
[0065] The glucose-responsive insulin microneedle patch is prepared by polymerization of the second functional material of the present invention and a phenylboronic acid monomer, and the glucose-responsive insulin microneedle patch has better glucose responsiveness, better biocompatibility, and higher insulin loading. Therefore, the present invention provides the application of the second functional material of the present invention in the preparation of the glucose-responsive insulin microneedle patch. The present invention also provides a second functional material as shown in formula II and a preparation method thereof. The preparation method of the second functional material comprises: in an inert solvent, D-(+)-gluconate delta-lactone and a compound of formula I react to generate the second functional material.
[0066]
[0067] In some embodiments, in Formula I and Formula II, n is selected from 1, 2, 3 or 4.
[0068] Herein, an inert solvent refers to a solvent that does not participate in the chemical reaction. The inert solvent may be a conventional solvent in the art, as long as it has no adverse effect on the reaction. In some embodiments, the inert solvent is selected from one or both of methanol and triethylamine; preferably, the inert solvent is a mixed solvent of methanol and triethylamine. In the mixed solvent of methanol and triethylamine, the volume ratio of methanol to triethylamine is 1:10-10:1, for example (7-10):1.
[0069] In some embodiments, the molar ratio of D-(+)-glucono delta-lactone to the compound of formula I may be 1:100-1:1, for example (1-10):1 or (1-5):1.
[0070] In some embodiments, the reaction temperature is 0-50° C., such as 10-35° C. or 20-30° C. In some embodiments, the reaction is carried out at room temperature (25° C.).
[0071] In some embodiments, the reaction time may be 1-10 hours, such as 3-8 hours.
[0072] The present invention provides a glucose-responsive insulin microneedle patch prepared using the method of the present invention. The glucose-responsive insulin microneedle patch is composed of a substrate and microneedles. In some embodiments, the glucose-responsive insulin microneedle patch includes a substrate and a microneedle array disposed on the substrate.
[0073] In some embodiments, the present invention provides a glucose-responsive insulin microneedle patch, comprising a substrate and a microneedle array formed on the substrate, wherein the substrate and the microneedle array are respectively formed by photopolymerization and curing of a first functional material and a second functional material in the presence of a solvent monomer, a crosslinking agent, and a photoinitiator, and the microneedle array contains drug molecules;
[0074] The first functional material is a compound represented by the following formula A, and its tautomers:
[0075]
[0076] In formula A, R is selected from C2-C6 alkenyl and -NH-CO-C2-C6 alkenyl;
[0077] The second functional material has a structure shown in Formula II:
[0078]
[0079] wherein n is selected from 1, 2, 3 or 4;
[0080] The first functional material, the second functional material, the solvent monomer, the cross-linking agent, the photoinitiator and the drug molecule are as described in any embodiment herein.
[0081] The substrate may be of any shape. In some embodiments, the substrate is square, rectangular, or circular. The area of the substrate may be 0.25-25 cm 2 , for example 0.5cm 2 , 1cm 2 , 5cm 2 , 10cm 2 , 20cm 2 , or between any two numerical ranges. The substrate thickness may be 500-5000 μm, such as 800 μm, 1000 μm, 2000 μm, 3000 μm, 4500 μm, or between any two numerical ranges. When the substrate is square or rectangular, the side length of the substrate may be 0.5-5 cm, such as 1 cm, 2 cm, 3 cm, 4 cm, or between any two numerical ranges. When the substrate is circular, the diameter of the substrate may be 0.5-5 cm, such as 1 cm, 2 cm, 3 cm, 4 cm, or between any two numerical ranges.
[0082] The microneedle may be a tetrahedral pyramid or a conical cone, preferably a tetrahedral pyramid. The height of the microneedle may be 400-4000 μm, such as 500 μm, 600 μm, 800 μm, 1000 μm, 3000, or between any two numerical ranges. When the microneedle is a tetrahedral pyramid, the side length of the square at its bottom may be 200-1000 μm, such as 250 μm, 300 μm, 500 μm, 800 μm, or between any two numerical ranges. When the microneedle is conical, the diameter of the circular bottom may be 200-1000 μm, such as 250 μm, 300 μm, 500 μm, 800 μm, or between any two numerical ranges. The microneedle tip spacing may be 100-1000 μm, such as 200 μm, 300 μm, 500 μm, 800 μm, or a range between any two values. The microneedle array may have a specification of 10×10-100×100, such as 10×15, 10×20, 10×30, 15×15, 15×30, 50×50, 80×80, or a range between any two values.
[0083] In some embodiments, the glucose-responsive insulin microneedle patch of the present invention can be loaded with 0.01-4 mg insulin, for example, 0.05 mg, 0.08 mg, 0.1 mg, 0.3 mg, 0.5 mg, 0.8 mg, 1 mg, 2 mg, 3 mg, or a range between any two numerical values.
[0084] In some embodiments, the swelling degree of the glucose-responsive insulin microneedle patch can reach 200-400% within 1 hour, such as 250-350% or 280-320%.
[0085] The glucose-responsive insulin microneedle patch prepared by the present invention can respond to changes in glucose concentration and release insulin. Therefore, the present invention provides the application of the glucose-responsive insulin microneedle patch of the present invention in the treatment of diabetes. When the glucose-responsive insulin microneedle patch of the present invention is in an environment with a glucose concentration of ≤400 mg / mL, the release rate of insulin in the glucose-responsive insulin microneedle patch of the present invention increases with the increase of the glucose concentration in the environment. Therefore, when the microneedle array of the glucose-responsive insulin microneedle patch is in an environment with a lower glucose concentration, the content of insulin released by the glucose-responsive insulin microneedle patch will decrease therewith, so that the subject using the glucose-responsive insulin microneedle patch to treat diabetes will not produce the phenomenon of hypoglycemia.
[0086] The present application provides the use of the glucose-responsive insulin microneedle patch of the present application in the preparation of a medicine kit.
[0087] The application provides a medicine box containing glucose responsive insulin microneedle patch of the present invention. The medicine box can be used for treating and / or preventing diabetes. The medicine box can also include instructions for relevant prevention, treatment, and / or control of diabetes (e.g., using independent glucose responsive insulin microneedle patch of the present invention or using in combination with another preventive agent or therapeutic agent), as well as side effects and application method dosage information.
[0088] The present invention provides a method for treating diabetes, comprising applying the glucose-responsive insulin microneedle patch of the present invention to the skin of a subject, wherein the glucose-responsive insulin microneedle patch is as described in any embodiment of the present invention.
[0089] The present invention has the following beneficial effects:
[0090] 1. The present invention uses a new monomer second functional material with good biocompatibility (e.g., D-glucosamidoethyl methacrylate) to prepare the glucose-responsive insulin microneedle patch of the present invention. The glucose-responsive insulin microneedle patch prepared using the second functional material of the present invention has better glucose responsiveness, better biocompatibility, and higher insulin loading.
[0091] 2. The preparation process of the present invention is simple, time-saving, and has a large insulin loading capacity (the maximum loading capacity can reach 4 mg). The glucose response performance and drug release rate can be controlled by controlling the ratio of the first functional material to the second functional material (for example, controlling the ratio of 3-acrylamidophenylboronic acid and D-glucosamidoethyl methacrylate), thereby responding to different physiological conditions.
[0092] 3. The glucose-responsive insulin microneedle patch of the present invention has a regular structure and excellent mechanical properties. It can effectively penetrate the skin, swell in contact with tissue fluid, and release insulin. Because of the dynamic covalent binding of the phenylboronic acid group and the ortho-dihydroxyl group, insulin can be released dynamically according to the glucose concentration in the skin interstitial fluid. Insulin is released quickly when blood sugar is high, and insulin is released slowly when blood sugar is low.
[0093] 4. The glucose-responsive insulin microneedle patch of the present invention has excellent mechanical strength, can puncture the skin, and intelligently release the insulin carried in the body according to the blood sugar concentration, and intelligently regulate the blood sugar level. The present invention realizes painless and intelligently responsive blood sugar regulation.
[0094] 5. When the concentration of glucose is within 400 mg / mL, the release rate of insulin in the glucose-responsive insulin microneedle patch of the present invention increases with the increase of glucose concentration.
[0095] 6. The use of glucose-responsive insulin microneedle patches to treat diabetes in animals (such as mice) can control the blood glucose concentration of the animals to a normal level (≤200 mg / dL) within 5-10 hours without causing hypoglycemia.
[0096] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0097] Herein, room temperature is 25±3°C.
[0098] In this article, porcine insulin was purchased from Xuzhou Wanbang Pharmaceutical, UP221001.
[0099] In this article, the microneedle mold was purchased from Taizhou Microchip Medical Technology, A57.
[0100] Preparation Example 1: Preparation of the second functional material
[0101] Weigh D-(+)-glucono δ-lactone (10.0 g) into a single-necked flask, add 100 mL of methanol solution, and then add the intermediate AEMA (2-aminoethyl methacrylate hydrochloride, CAS: 2420-94-2) (12.0 g) and 12 mL of triethylamine into the flask. After reacting at room temperature for 3 hours, vacuum filter and concentrate the filtrate by rotary evaporation. Vacuum filter again and dry the filter cake in an infrared oven to obtain 47.0 mg of white precipitate D-glucosamidoethyl methacrylate with a yield of 27.3%. The NMR spectrum is as follows: Figure 1 shown.
[0102] Repeat the same experimental steps and use methacrylic acid aminomethyl ester hydrochloride to replace AEMA to obtain D-glucosamidomethyl methacrylate. Repeat the same experimental steps and use methacrylic acid 3-aminopropyl ester hydrochloride to replace AEMA to obtain D-glucosamidopropyl methacrylate.
[0103]
[0104] D-Gluconamidomethyl methacrylate D-Gluconamidopropyl methacrylate
[0105] Preparation Example 2: Preparation of Rhodamine-labeled porcine insulin
[0106] Put 100 mg of porcine insulin into 25 mL of a buffer solution of Na2CO3 and NaHCO3 at pH 9.0. Then weigh 1.5 mg of rhodamine isothiocyanate B and dissolve it in 1.5 mL of DMSO. Then slowly drip the rhodamine isothiocyanate B solution into the porcine insulin solution and react at room temperature in the dark for 2 hours. After the reaction is completed, transfer the reaction solution to a dialysis bag (molecular cutoff: 1000 Da) and dialyze for 72 hours in the dark, replacing ultrapure water every 12 hours. After the dialysis is completed, transfer the dialysate to a centrifuge tube and freeze-dry to obtain red solid powder rhodamine-labeled porcine insulin.
[0107] Example 1
[0108] Weigh 3-acrylamidophenylboronic acid (143.0 mg), D-glucosamidoethyl methacrylate (57.0 mg), porcine insulin (20 mg) and photoinitiator 2959 (21.0 mg) in a 5 mL centrifuge tube, add 1 mL of N-vinyl pyrrolidone to the tube, sonicate to completely dissolve it, then add crosslinker ethylene glycol dimethacrylate (8.8 μL) to the system, sonicate again for 30 min to mix, and prepare the needle body solution. As described above, a base solution without active pharmaceutical ingredients is prepared without adding insulin. Use a pipette to draw 50 μL of needle body solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Use a pipette to draw 50 μL of base solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Finally, place the mold under a laser (196 W, 365 nm) for 10 min. After the light irradiation, the cured microneedle patch was demolded from the mold and placed in a desiccator for 48 hours. The glucose-responsive insulin microneedle patch was characterized using a scanning electron microscope. Figure 2 As shown, a regular 15×15 microneedle array with a height of about 550 μm, a bottom width of 250 μm, and a needle tip distance of 500 μm is formed. The base of the microneedle patch is a square, the base side length is 1 cm, and the base thickness is 2 mm. The microneedles of this height are sufficient to reach the dermis of the skin tissue to achieve insulin delivery. The swelling rate of the glucose-responsive insulin microneedle patch prepared in this embodiment for 1 hour is 300%.
[0109] Example 2
[0110] Weigh 3-acrylamidophenylboronic acid (71.5 mg), D-glucosamidoethyl methacrylate (28.5 mg), rhodamine-labeled porcine insulin (8 mg) and photoinitiator 2959 (21.0 mg) in a 5 mL centrifuge tube, add 1 mL of N-vinyl pyrrolidone to the tube, sonicate to completely dissolve it, then add crosslinker ethylene glycol dimethacrylate (8.8 μL) to the system, sonicate again for 30 min to mix, and prepare the needle body solution. As described above, a base solution without active pharmaceutical ingredients is prepared without adding insulin. Use a pipette to draw 50 μL of the needle body solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Use a pipette to draw 50 μL of the base solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Finally, place the mold under a laser (196 W, 365 nm) for 10 min. After the light irradiation, the cured microneedle patch was demolded from the mold and placed in a desiccator for 48 hours. The glucose-responsive insulin microneedle patch was observed using a fluorescent inverted microscope. Figure 3 It can be observed that the fluorescent label is mainly located at the needle body, indicating that insulin is evenly distributed at the microneedle tip and loaded into each microneedle.
[0111] Example 3
[0112] Weigh 3-acrylamidophenylboronic acid (286.0 mg), D-glucosamidoethyl methacrylate (57.0 mg), porcine insulin (8 mg) and photoinitiator 2959 (21.0 mg) in a 5 mL centrifuge tube, add 1 mL of N-vinyl pyrrolidone to the tube, sonicate to completely dissolve it, then add crosslinker ethylene glycol dimethacrylate (8.8 μL) to the system, sonicate again for 30 min to mix, and prepare the needle body solution. As described above, a base solution without active pharmaceutical ingredients is prepared without adding insulin. Use a pipette to draw 50 μL of the needle body solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Use a pipette to draw 50 μL of the base solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Finally, place the mold under a laser (196 W, 365 nm) for 10 min. After the light irradiation is completed, the cured microneedle patch is demolded from the mold and placed in a desiccator for drying for 48 hours.
[0113] Example 4
[0114] Weigh 3-acrylamidophenylboronic acid (107.3 mg), D-glucosamidoethyl methacrylate (57.0 mg), porcine insulin (8 mg) and photoinitiator 2959 (21.0 mg) in a 5 mL centrifuge tube, add 1 mL of N-vinyl pyrrolidone to the tube, sonicate to completely dissolve it, then add crosslinker ethylene glycol dimethacrylate (8.8 μL) to the system, sonicate again for 30 min to mix, and prepare the needle body solution. As described above, a base solution without active pharmaceutical ingredients is prepared without adding insulin. Use a pipette to draw 50 μL of needle body solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Use a pipette to draw 50 μL of base solution and add it to the center of the microneedle mold, and then place the mold in a centrifuge at 5000 rpm for 10 min. Finally, place the mold under a laser (196 W, 365 nm) for 10 min. After the light irradiation is completed, the cured microneedle patch is demolded from the mold and placed in a desiccator for drying for 48 hours.
[0115] Example 5
[0116] The glucose-responsive insulin microneedle patch prepared in Example 1 was subjected to an insulin responsive performance study. The glucose-responsive insulin microneedle patch was co-incubated with 1 mL PBS (pH = 7.4) solution of different glucose concentrations (0, 100, 200, 400 mg / dL) at 37°C. 10 μL of supernatant was collected in a 96-well plate within a predetermined time. According to the experimental steps of the Bradford protein concentration determination kit, 300 μL of staining solution was added to all sample wells. The absorbance of the solution at 595 nm was measured in an ELISA instrument. A standard curve of insulin concentration was drawn. The insulin concentration was calculated according to the standard curve and a curve was drawn. Figure 4 The figure shows that in solutions with different glucose concentrations, the release rate of insulin increases with the increase of glucose concentration. This shows that the prepared microneedle patch has glucose responsiveness.
[0117] Example 6
[0118] Glucose-responsive insulin microneedle patches with insulin doses of 0.4, 0.6 and 0.8 mg were prepared in the same manner as in Example 1.
[0119] The insulin microneedle patch was applied to C57 mice with type 1 diabetes induced by streptozotocin to evaluate its blood sugar regulation ability in diabetic mice. Five diabetic mice were selected, and the backs of the mice were first depilated, and the mice were fasted for 12 hours before the experiment. Glucose-responsive insulin microneedle patches containing different insulin doses (0.4, 0.6 and 0.8 mg) were applied to the backs of the mice, and then the patches were pressed with the thumb for 5 minutes to ensure that the microneedle tips were completely inserted into the mouse skin, and finally the patches were fixed with medical tape. According to the same method and process as above, a microneedle patch without insulin loading was applied to the back of the mouse as a blank control (the raw materials for the preparation of the microneedle patch of the blank control were all base solutions). The positive control was the subcutaneous administration of porcine insulin 15IU / Kg on the back of the mouse. After the patch was applied, blood was taken from the tail vein every 30 minutes to measure the blood sugar of the mice for 12 hours, and water was not allowed during this period. The blood sugar change curve of diabetic mice over time during the experiment was recorded and plotted. The results are shown in Figure 5 The microneedle patch can continuously control blood sugar within the normoglycemic range (<200 mg / dL) for up to 8 hours, after which blood sugar levels gradually increase without hypoglycemia.
Claims
1. A glucose-responsive insulin microneedle patch, comprising a substrate and a microneedle array formed on the substrate, wherein: The substrate and the microneedle array are respectively formed by photopolymerization and curing of a first functional material and a second functional material in the presence of a solvent monomer, a crosslinking agent and a photoinitiator, and the microneedle array contains drug molecules; The first functional material is a compound represented by the following formula A, and its tautomers: In formula A, R is selected from C2-C6 alkenyl and -NH-CO-C2-C6 alkenyl; The second functional material has a structure shown in Formula II: wherein n is selected from 1, 2, 3 or 4.
2. The glucose-responsive insulin microneedle patch according to claim 1, characterized in that: The glucose-responsive insulin microneedle patch has one or more of the following characteristics: The solvent monomer is selected from one or more of N-vinyl pyrrolidone, hydroxyethyl methacrylate, ethyl methacrylate and ethyl 3-(dimethylamino)acrylate; The first functional material is selected from one or more of 2-acrylamidophenylboronic acid, 3-acrylamidophenylboronic acid, 4-acrylamidophenylboronic acid and 4-vinylphenylboronic acid; The second functional material is selected from one or more of D-glucosamidomethyl methacrylate, D-glucosamidoethyl methacrylate and D-glucosamidopropyl methacrylate; The crosslinking agent is selected from one or more of 1,4-butylene glycol diacrylate, itaconic acid, methacrylic acid, methylene bisacrylamide and ethylene glycol dimethacrylate; The photoinitiator is selected from one or more of phenyl-2,4,6-trimethylbenzoyl lithium phosphinate, 2,4,6-trimethylbenzoyl diphenylphosphine, phenyl bis (2,4,6-trimethylbenzoyl), ethyl 2,4,6-trimethylbenzoyl phenylphosphonate and 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone; The drug molecule is selected from one or more of animal insulin, human insulin and human insulin analogs; preferably, the human insulin analogs are selected from one or more of lispro insulin, glargine insulin, aspart insulin and detemir insulin.
3. The glucose-responsive insulin microneedle patch according to claim 1, characterized in that: The glucose-responsive insulin microneedle patch has one or more of the following characteristics: The substrate is square, rectangular or circular, with a side length or diameter of preferably 0.5-5 cm, a thickness of preferably 500-5000 μm, and an area of preferably 0.25-25 cm 2 ; The microneedle is in the shape of a quadrangular pyramid or a cone, the height of the microneedle is preferably 400-4000 μm, and the side length or diameter of the bottom of the microneedle is preferably 200-1000 μm; The specification of the microneedle array is 10×10-100×100; The microneedle tip spacing is 100-1000 μm.
4. The glucose-responsive insulin microneedle patch according to claim 1, characterized in that: The glucose-responsive insulin microneedle patch has one or more of the following characteristics: When the concentration of glucose is within 400 mg / mL, the release rate of insulin in the glucose-responsive insulin microneedle patch increases with the increase of glucose concentration; The glucose-responsive insulin microneedle patch is loaded with 0.01-4 mg of insulin; The swelling degree of the glucose-responsive insulin microneedle patch within 1 hour is 200-400%.
5. A method for preparing the glucose-responsive insulin microneedle patch according to any one of claims 1 to 4, characterized in that: Includes steps: (1) preparing a base solution and a needle solution, wherein the base solution comprises a solvent monomer, a functional material, a cross-linking agent and a photoinitiator; and the needle solution comprises a solvent monomer, a functional material, a cross-linking agent, a photoinitiator and a drug molecule; (2) placing the needle body solution in a microneedle mold, wherein the needle body solution is completely distributed in the needle body portion of the microneedle mold, and then adding the base solution into the microneedle mold; (3) placing the microneedle mold containing the needle body solution and the substrate solution obtained in step (2) under ultraviolet light to cause the needle body solution and the substrate solution to undergo a polymerization reaction to form a cured microneedle patch; (4) Drying the solidified microneedle patch to obtain the glucose-responsive insulin microneedle patch.
6. The method according to claim 5, characterized in that: The method has one or more of the following features: In the needle solution, the mass percentage of each component is: the solvent monomer is 58%-90%, the first functional material is 2-30%, the second functional material is 1-10%, the cross-linking agent is 0.1%-5%, the photoinitiator is 0.1%-2%, and the drug molecule is 0.01%-30%; In the base solution, the mass percentage of each component is: the solvent monomer is 50%-95%, the first functional material is 2-30%, the second functional material is 1-10%, the cross-linking agent is 0.1%-5%, and the photoinitiator is 0.1%-2%; In the needle solution and the substrate solution, the molar ratio of the first functional material to the second functional material is (20:1) to (1:10).
7. The method according to claim 5, characterized in that The method has one or more of the following features: In step (2), the needle body solution is placed in a microneedle mold and centrifuged once, so that the needle body solution is completely distributed in the needle body part of the microneedle mold; then the base solution is added to the microneedle mold and centrifuged twice; In step (2), the rotation speed of the first centrifugation is 4000-6000 rpm; In step (2), the time of one centrifugation is 2-30 min; In step (2), the secondary centrifugation speed is 4000-6000 rpm; In step (2), the secondary centrifugation time is 2-30 min; In step (3), the wavelength of the ultraviolet light is 330-420 nm; In step (3), the power of the ultraviolet light is 100-300w; In step (3), the ultraviolet light irradiation time is 5-20 minutes; In step (4), the drying time is 24-72 hours.
8. The method according to claim 5, characterized in that The preparation method of the second functional material represented by formula II comprises: in an inert solvent, D-(+)-glucono delta-lactone and a compound of formula I react to generate the second functional material, wherein n is selected from 1, 2, 3 or 4.
9. The method according to claim 8, characterized in that The preparation method of the second functional material has one or more of the following characteristics: The inert solvent is selected from one or both of methanol and triethylamine; The molar ratio of D-(+)-glucono delta-lactone to the compound of formula I is 1:100-1:1; The reaction temperature is 0-50°C; The reaction time is 1-10h.
10. Application of the second functional material represented by formula II in the preparation of glucose-responsive insulin microneedle patch:
